Official Account of the NCI's Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Network; https://xitter.cf/t.co/U1h0pPxOF0

Joined September 2022
Launched by @theNCI in 2021, Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) aims to develop a network for collaborative research in precision cancer prevention and interception. More info: t.ly/wlcI_ or ncicapit.org.
2
1
6
1,307
Save the date! The Cancer Prevention Research Conference brings researchers together to advance prevention from discovery biology to population science. 📍 London | June 23–25, 2027 🗓️ Abstract deadline: March 21, 2027 #CancerPrevention cancerresearchuk.org/for-res…
1
1
57
Organoids and organs-on-chips are transforming oncology. I advise researchers to ask, 'why default to standard animal models? Does a more precise human-relevant option exist?' Explore @theNCI’s Human Cancer Models Initiative database: go.nih.gov/bH7iy3k
1
23
2
80
7,894
CAP-IT retweeted
NEWS: NIH launches new resource accessible through PubMed to strengthen research replication and reproducibility. Read the full story ➡️ bit.ly/4y7rXtA
8
23
2
112
46,962
New paper from Stephanie Dougan @DanaFarber_Hale with @NobelPrize David Baker in @CellCellPress! CD4 T cells convert transient responses to KRAS inhibition to durable remissions in #PancreaticCancer cell.com/cell/fulltext/S0092… Synthetic cytokines for the win! #AACRPan26
4
40
142
9,435
At today’s #CAPITSCMeeting, Dr. Shizuko Sei thanked outgoing SC Chair Dr. Yong Li for his contributions to the network and welcomed incoming Chair Dr. Margie Clapper, who shared brief remarks. Dr. Sei provided NCI updates, while WG Chairs Drs. Alan Hutson @Amherst73 and Clapper highlighted recent activities and upcoming plans. Dr. Warren Casey, Director of the NIH Office of Research Innovation, Validation, and Application (ORIVA), presented NIH efforts to advance human-based science, an important and timely topic for many investigators and helped clarify common questions and misconceptions.
1
75
📢 Upcoming Workshop: Alternative Methodologies in Pharmaceutical Development Join @theNCI and @NIH ORIVA (Office of Research Innovation, Validation, and Application) on Oct. 20–21, 2026, to explore the current and future applications of New Approach Methodologies (NAMs) in drug development, safety, efficacy, and disease modeling. 📍 Rockville, MD + webcast 🔗 Register & learn more: ntp.niehs.nih.gov/go/ampd-wk… #CancerResearch #NAMs #DrugDevelopment #3Rs
1
1
54
New NIH Highlighted Topic: Accelerating Disease Prevention Research by New Approach Methodologies (NAMs) NCI is encouraging applications using human-relevant NAMs to advance precancer biology, cancer prevention, and cancer interception:from organoids and bioengineered tissues to in silico models. Learn more: grants.nih.gov/funding/find-… #CancerPrevention #CancerInterception #Precancer #NAMs #CancerResearch
1
1
57
The NCI DCP-IIG Immunoprevention Webinar Series welcomes Dr. Catherine Wu @DanaFarber on Sept. 9, 2026, for a discussion on personalized cancer vaccines. Dr. Wu will highlight advances in antigen discovery, tumor–immune interactions, and recent clinical trial findings, while addressing key challenges and future directions for the field. 🔗 events.cancer.gov/dcp/IIG?ci… #Immunoprevention #CancerVaccines #CancerResearch
1
2
149
📢 New #CAPITPublication! Congratulations to CAP-IT @FoxChaseCancer Dr. Margie Clapper and Dr. Erica Golemis and colleagues on their new review, “Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD),” published in Cancer and Metastasis Reviews. 🔗pubmed.ncbi.nlm.nih.gov/4259… The review highlights advances in understanding VHL biology and explores emerging strategies for the treatment, prevention, and interception of cancer in individuals with VHLD. #CancerPrevention #CancerInterception #VHLD #CancerResearch
1
136
Take a listen to the first episode of #CAPITPodcast! 🔗capit.riverside.com/ Dr. Margie Clapper of @FoxChaseCancer talks with Erica Kirschner of @LFSAssociation in a candid, touching, and inspiring conversation about living with hereditary cancer risk, and the promise of cancer prevention and interception.
🤖 Made with AI
1
46
One of the biggest questions in translational oncology is whether we can demonstrate that cancer models can faithfully represent patient biology. A new @Nature study provides evidence that NCI's Human Cancer Models Initiative does just that. go.nih.gov/IDoYiIW
3
28
2
73
15,494
Worth revisiting: “NCI Resources for Cancer Immunoprevention Research,” published in @CIR_AACR , highlights NCI-supported resources available to advance cancer immunoprevention research, from preclinical models and data resources to clinical and translational research tools.A valuable resource for the #CAPIT community and the broader cancer prevention field. 🔗aacrjournals.org/cancerimmun… #CancerImmunoprevention #CancerPrevention #NCI #Immunology
1
33